Convertible Debentures (Details Narrative) - USD ($)				3 Months Ended			9 Months Ended
		Feb. 10, 2012	May 03, 2011	Sep. 30, 2016		Sep. 30, 2015	Sep. 30, 2016		Sep. 30, 2015
Percentage of royalty revenue							2.50%
Percentage of discount on conversion price							30.00%
Debt instrument maturity date							May 27, 2011
Research and development costs				$ 10		$ 931	$ 1,425		$ 1,897
Debt indstrument principal balance				$ 125,000			$ 125,000
Convertible Debenture One [Member]
Debt instrument maturity date	[1]						May 27, 2011
Debt instrument, convertible, beneficial conversion feature							$ 53,517
Research and development costs							$ 71,483
Debt indstrument principal balance		$ 125,000
Long-term debt, gross		7,500
Debt instrument transfer or assignment in second closing		11,750
Debt instrument transfer or assignment in subsequent closing		$ 11,750
Debt instrument interest percentage	[1]			10.00%			10.00%
Convertible Debenture Two [Member]
Percentage of discount on conversion price			30.00%
Debt instrument maturity date	[2]						May 05, 2012
Borrowing convertible debenture			$ 300,000
Debt instrument interest percentage			10.00%	10.00%	[2]		10.00%	[2]
Reverse stock split			1 for -1,350
Debt discount			$ 206,832
Fair market value of warrants			$ 45,000
Convertible Debenture Two [Member] | Warrant One [Member]
Number of warrants granted			300,000
Warrants exercise price per share			$ 337.50
Convertible Debenture Two [Member] | Warrant Two [Member]
Number of warrants granted			600,000
Warrants exercise price per share			$ 472.50
Convertible Debenture Three [Member]
Percentage of discount on conversion price							30.00%
Debt instrument maturity date	[3]						Aug. 31, 2013
Borrowing convertible debenture				$ 10,000			$ 10,000
Debt instrument interest percentage	[3]			5.00%			5.00%
Accreted interest expense							$ 4,286

[1] (1) The Company purchased in exchange for convertible debenture exclusive rights for license of certain intellectual property from an unrelated party. The parties agreed to a royalty of 2.5% of net revenues generated from the sale, sub-license or use of the technology or a reasonable negotiated rate based on similar invention. The debenture was convertible to common shares of the Company at May 27, 2011, along with accrued interest at the option of the lender. Conversion price per share is 30% discount as determined from the weighted average of the preceding 12 trading days' closing market price. The Company valued the BCF of the convertible debenture at $53,517, its intrinsic value. The Company accreted the discount to the convertible debenture and will recognize interest expense through repayment in full or conversion. Because there was no assurance of success and the invention was still in design and pre-prototype phase, the Company recorded the initial net value of the debenture, $71,483, as research and development expense during the year ended 2010. Both parties agreed to confidentiality regarding the invention during the pre-prototype stage. In addition, the Company agreed to provide the licensor with design services, as well as assist in completing the prototype and initial production at the Company's prevailing wholesale rate for comparable services. on February 10, 2012, the holder of this debenture entered into an agreement with a third party to sell/assign the $125,000 principal balance, plus accrued interest. The purchase was to be in installments with transfer/assignment of the debenture upon payment, referred to as ;Closings”. The first Closing was on or about February 15, 2012 for $7,500, with that amount assigned/transferred. The second Closing, occurred 90 days after the first closing for $11,750 paid/assigned. All subsequent Closings were to be for $11,750 and occur in 30 day increments after the second Closing. This was to continue until the full principal balance of $125,000, plus accrued interest is purchased or assigned. The holder of the convertible note has voluntarily dissolved and ceased operation. In February 2016 both parties agreed to cancel the agreement and all remaining principal and interest balances.

[2] (2) On May 3, 2011, the Company borrowed $300,000 in exchange for a convertible debenture. The Debenture bears 10% interest per annum. The lender may at any time convert any portion of the debenture to common shares at a 30% discount of the "Market Price" of the stock based on the average of the previous ten (10) days weighted average closing prices on the date prior to the notice of conversion. The Company may prepay the debenture plus accrued interest at any time before maturity. In addition, as further inducement for loaning the Company the funds, the Company granted the lender 300,000 and 600,000 warrants at $337.50 and $472.50 per share (after restatement for 1 for -1,350- reverse stock split), respectively. As a result, the Company allocated fair market value ("FMV") to both the BCF and to the warrants, or $206,832, which was recorded as a discount against the debenture. The Company accreted the discount to the convertible debenture through maturity and will accrue interest expense until paid in full or converted. Before discount, the Company determined the FMV of the warrants as $45,000 using the Black-Scholes valuation model.

[3] (3) The Company borrowed $10,000 in exchange for a convertible debenture. The lender at their option may convert all or part of the note plus accrued interest into common stock at a price of thirty percent (30%) discount as determined from the average four (4) highest closing bid prices over the preceding five (5) trading days. The Company valued the BCF of the convertible debenture at $4,286, which was accreted to interest expense.